A team at 1st Bio Therapeutics Inc. has identified indazoles acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Chengdu Easton Biopharmaceuticals Co. Ltd. has synthesized aminopyridine derivatives acting as CDK9/cyclin T1 inhibitors reported to be useful for the treatment of cancer.
Gilead Sciences Inc. and Assembly Biosciences Inc. have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
Researchers from Biolexis Therapeutics Inc. presented the development of a potent and highly selective CDK9 inhibitor, BLX-3030, and its analogues for the treatment of N-Myc and c-Myc-driven cancers.
Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company’s second program within its SAYA Y-PRIT (Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy) theranostic platform.
Researchers from Generate Biomedicines Inc. have detailed the discovery and preclinical characterization of GB-0669, a spike S2-targeted monoclonal antibody (MAb) being developed for the prophylaxis of SARS-CoV-2 infection. Machine learning models were used to identify MAbs targeting the conserved S2 stem helix and RBD class IV region of spike.
Bloomsbury Genetic Therapies Ltd. has announced U.S. and E.U. orphan drug designations for BGT-NPC, an investigational gene therapy for the treatment of Niemann-Pick disease type C (NPC). BGT-NPC is an investigational AAV9 gene therapy designed to provide a potentially curative solution to NPC patients following a one-time injection in the cerebrospinal fluid.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel small-molecule diacylglycerol kinase ζ (DGKζ) inhibitor ASP-1570, currently in phase I development for the treatment of solid tumors (NCT05083481).
Monte Rosa Therapeutics Inc. has entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop molecular glue degraders against targets in cancer and neurological diseases previously considered impossible to drug.